Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Manganese-Enhanced MRI (MEMRI) to Assess Peri-Infarct Injury

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: PHASE1/PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~All subjects to be entered must:~* be at least 18 years of age.~* if female, be nonpregnant as evidenced by a serum pregnancy test and using a medically-approved method of birth control, or post-menopausal or surgically sterile~* provide written informed consent after having received oral and written information about the study~* be in stable health based on medical history, examination and tests~Exclusion Criteria:~have a positive pregnancy test (females)~* received an investigational drug or device within 30 days prior to administration of SeeMore~* have known hypersensitivity to ondansetron or other selective serotonin 5HT3 receptor blockers~* have a history of drug abuse or alcoholism~* are taking a digitalis preparation or calcium channel blocker~* have a history of torsades or prolonged QT/QTc interval~* have NYHA Grade IV heart failure~* have abnormal liver function tests or a history of liver disease~* have uncontrolled hypertension (Systolic Blood Pressure \> 140 or Diastolic BP \> 90 consistently at baseline)~* have abnormal baseline potassium or calcium values or hemoglobin less than 10 g/dl~* are noncompliant or otherwise unlikely to perform as required by the protocol~* have pretest likelihood of CAD for which the requisite number of subjects have been entered~* develop an arrhythmia prior to or during either of the exercise tests; SeeMore should not be administered.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 70 Years
- Healthy Volunteers: f

Study Arms:
- Coronary Disease (Type: EXPERIMENTAL): Participant receive 2 cardiac MRI procedures: MEMRI and DEMRI.

Based on this trial design, predict the completion outcome and termination type (if applicable).